<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36012563</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson's Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9299</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23169299</ELocationID><Abstract><AbstractText>Neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) are both characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. Both diseases lack biomarkers for diagnosis and treatment efficacy. Proteomics is an unbiased quantitative tool capable of the high throughput quantitation of thousands of proteins from minimal sample volumes. We review recent proteomic studies in human tissues, plasma, cerebrospinal fluid (CSF), and exosomes in ALS and PD that identify proteins with potential utility as biomarkers. Further, we review disease-related post-translational modifications in key proteins TDP43 in ALS and &#x3b1;-synuclein in PD studies, which may serve as biomarkers. We compare relative and absolute quantitative proteomic approaches in key biomarker studies in ALS and PD and discuss recent technological advancements which may identify suitable biomarkers for the early-diagnosis treatment efficacy of these diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raghunathan</LastName><ForeName>Rekha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bioanalytical and Biomarker, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turajane</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bioanalytical and Biomarker, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Li Chin</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Bioanalytical and Biomarker, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">LC-MS/MS</Keyword><Keyword MajorTopicYN="N">PD</Keyword><Keyword MajorTopicYN="N">TDP43</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword></KeywordList><CoiStatement>All authors are employees of Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36012563</ArticleId><ArticleId IdType="pmc">PMC9409485</ArticleId><ArticleId IdType="doi">10.3390/ijms23169299</ArticleId><ArticleId IdType="pii">ijms23169299</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbott E.O., Malek A.M., Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb. Clin. Neurol. 2016;138:225&#x2013;238. doi: 10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar S., Ellis M., Abdul-Aziz N.A., Goh K.J., Shahrizaila N., Kennerson M.L., Ahmad-Annuar A. Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS) Neurobiol. Aging. 2021;108:200&#x2013;206. doi: 10.1016/j.neurobiolaging.2021.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.07.008</ArticleId><ArticleId IdType="pubmed">34404558</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B.N., Newhouse S., Shatunov A., Vance C., Topp S., Johnson L., Miller J., Lee Y., Troakes C., Scott K.M., et al. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur. J. Hum. Genet. 2013;21:102&#x2013;108. doi: 10.1038/ejhg.2012.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.98</ArticleId><ArticleId IdType="pmc">PMC3522204</ArticleId><ArticleId IdType="pubmed">22692064</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M. Mutation in C9orf72 changes the boundaries of ALS and FTD. Lancet Neurol. 2012;11:205&#x2013;207. doi: 10.1016/S1474-4422(12)70020-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70020-0</ArticleId><ArticleId IdType="pubmed">22305803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L., He X., Cui B., Zhao F., Zhou C. NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): A meta-analysis. Neurol. Sci. 2021;42:1277&#x2013;1285. doi: 10.1007/s10072-020-05037-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-05037-6</ArticleId><ArticleId IdType="pubmed">33462636</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse H., Ishiura H., Mitsui J., Takahashi Y., Matsukawa T., Yoshimura J., Doi K., Morishita S., Goto J., Toda T., et al. Loss-of-function variants in NEK1 are associated with an increased risk of sporadic ALS in the Japanese population. J. Hum. Genet. 2021;66:237&#x2013;241. doi: 10.1038/s10038-020-00830-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s10038-020-00830-9</ArticleId><ArticleId IdType="pubmed">32920598</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley J.F., Fioramonti P.J., Rusnock A.K., Hehnly H., Castaneda C.A. ALS-linked mutations impair UBQLN2 stress-induced biomolecular condensate assembly in cells. J. Neurochem. 2021;159:145&#x2013;155. doi: 10.1111/jnc.15453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15453</ArticleId><ArticleId IdType="pmc">PMC8667623</ArticleId><ArticleId IdType="pubmed">34129687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin B.C., Phung T.H., Higgins N.R., Greenslade J.E., Prado M.A., Finley D., Karbowski M., Polster B.M., Monteiro M.J. ALS/FTD mutations in UBQLN2 are linked to mitochondrial dysfunction through loss-of-function in mitochondrial protein import. Hum. Mol. Genet. 2021;30:1230&#x2013;1246. doi: 10.1093/hmg/ddab116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab116</ArticleId><ArticleId IdType="pmc">PMC8212775</ArticleId><ArticleId IdType="pubmed">33891006</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron D.M., Fenton A.R., Saez-Atienzar S., Giampetruzzi A., Sreeram A., Shankaracharya, Keagle P.J., Doocy V.R., Smith N.J., Danielson E.W., et al. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 2022;39:110598. doi: 10.1016/j.celrep.2022.110598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110598</ArticleId><ArticleId IdType="pmc">PMC9134378</ArticleId><ArticleId IdType="pubmed">35385738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A., Kenna K.P., Renton A.E., Ticozzi N., Faghri F., Chia R., Dominov J.A., Kenna B.J., Nalls M.A., Keagle P., et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97:1268&#x2013;1283.e6. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S., Rajendra K.C., Alagar S., Bahadur R.P. Impaired nuclear transport induced by juvenile ALS causing P525L mutation in NLS domain of FUS: A molecular mechanistic study. Biochim. Biophys. Acta Proteins Proteom. 2022;1870:140766. doi: 10.1016/j.bbapap.2022.140766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2022.140766</ArticleId><ArticleId IdType="pubmed">35134572</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J., Bilbao J., Zinman L., Hazrati L.N., Tokuhiro S., Sato C., Moreno D., Strome R., Mackenzie I.R., Rogaeva E. A novel double mutation in FUS gene causing sporadic ALS. Neurobiol. Aging. 2011;32:553.e27&#x2013;553.e30. doi: 10.1016/j.neurobiolaging.2010.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.015</ArticleId><ArticleId IdType="pubmed">20561714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Mazzini L., D&#x2019;Alfonso S., Corrado L., Canosa A., Moglia C., Manera U., Bersano E., Brunetti M., Barberis M., et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology. 2018;91:e635&#x2013;e642. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson&#x2019;s disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257&#x2013;1272. doi: 10.1016/S1474-4422(16)30230-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30230-7</ArticleId><ArticleId IdType="pubmed">27751556</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Fu Y., Halliday G.M., Sue C.M. PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson&#x2019;s Disease. Front. Cell Dev. Biol. 2021;9:612476. doi: 10.3389/fcell.2021.612476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.612476</ArticleId><ArticleId IdType="pmc">PMC8291125</ArticleId><ArticleId IdType="pubmed">34295884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Luo X., Li F., Tian X., Zhu L., Yang Y., Ren Y., Pang H. Association of Parkinson&#x2019;s disease with six single nucleotide polymorphisms located in four PARK genes in the northern Han Chinese population. J. Clin. Neurosci. 2012;19:1011&#x2013;1015. doi: 10.1016/j.jocn.2011.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2011.09.028</ArticleId><ArticleId IdType="pubmed">22575062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung S.J., Armasu S.M., Biernacka J.M., Lesnick T.G., Rider D.N., Lincoln S.J., Ortolaza A.I., Farrer M.J., Cunningham J.M., Rocca W.A., et al. Common variants in PARK loci and related genes and Parkinson&#x2019;s disease. Mov. Disord. 2011;26:280&#x2013;288. doi: 10.1002/mds.23376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23376</ArticleId><ArticleId IdType="pmc">PMC3606822</ArticleId><ArticleId IdType="pubmed">21412835</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C., Schneider S.A., Lang A.E. Hereditary parkinsonism: Parkinson disease look-alikes&#x2014;An algorithm for clinicians to &#x201c;PARK&#x201d; genes and beyond. Mov. Disord. 2009;24:2042&#x2013;2058. doi: 10.1002/mds.22675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22675</ArticleId><ArticleId IdType="pubmed">19735092</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo A., Klein C. Genetics of Parkinson disease. Handb. Clin. Neurol. 2018;147:211&#x2013;227. doi: 10.1016/B978-0-444-63233-3.00014-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63233-3.00014-2</ArticleId><ArticleId IdType="pubmed">29325612</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer P.E., Holdt L.M., Teupser D., Mann M. Revisiting biomarker discovery by plasma proteomics. Mol. Syst. Biol. 2017;13:942. doi: 10.15252/msb.20156297.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20156297</ArticleId><ArticleId IdType="pmc">PMC5615924</ArticleId><ArticleId IdType="pubmed">28951502</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzhozovskiy A., Kononikhin A., Bugrova A.E., Kovalev G.I., Schmit P.O., Kruppa G., Nikolaev E.N., Borchers C.H. The Parallel Reaction Monitoring-Parallel Accumulation-Serial Fragmentation (prm-PASEF) Approach for Multiplexed Absolute Quantitation of Proteins in Human Plasma. Anal. Chem. 2022;94:2016&#x2013;2022. doi: 10.1021/acs.analchem.1c03782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c03782</ArticleId><ArticleId IdType="pubmed">35040635</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesur A., Dittmar G. The clinical potential of prm-PASEF mass spectrometry. Expert Rev. Proteom. 2021;18:75&#x2013;82. doi: 10.1080/14789450.2021.1908895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2021.1908895</ArticleId><ArticleId IdType="pubmed">33874828</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier F., Beck S., Grassl N., Lubeck M., Park M.A., Raether O., Mann M. Parallel Accumulation-Serial Fragmentation (PASEF): Multiplying Sequencing Speed and Sensitivity by Synchronized Scans in a Trapped Ion Mobility Device. J. Proteome Res. 2015;14:5378&#x2013;5387. doi: 10.1021/acs.jproteome.5b00932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b00932</ArticleId><ArticleId IdType="pubmed">26538118</ArticleId></ArticleIdList></Reference><Reference><Citation>Garabedian A., Benigni P., Ramirez C.E., Baker E.S., Liu T., Smith R.D., Fernandez-Lima F. Towards Discovery and Targeted Peptide Biomarker Detection Using nanoESI-TIMS-TOF MS. J. Am. Soc. Mass Spectrom. 2018;29:817&#x2013;826. doi: 10.1007/s13361-017-1787-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13361-017-1787-8</ArticleId><ArticleId IdType="pmc">PMC5844780</ArticleId><ArticleId IdType="pubmed">28889248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou C.C., Avtonomov D., Larsen B., Tucholska M., Choi H., Gingras A.C., Nesvizhskii A.I. DIA-Umpire: Comprehensive computational framework for data-independent acquisition proteomics. Nat. Methods. 2015;12:258&#x2013;264. doi: 10.1038/nmeth.3255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3255</ArticleId><ArticleId IdType="pmc">PMC4399776</ArticleId><ArticleId IdType="pubmed">25599550</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichev V., Messner C.B., Vernardis S.I., Lilley K.S., Ralser M. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods. 2020;17:41&#x2013;44. doi: 10.1038/s41592-019-0638-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0638-x</ArticleId><ArticleId IdType="pmc">PMC6949130</ArticleId><ArticleId IdType="pubmed">31768060</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinitcyn P., Hamzeiy H., Salinas Soto F., Itzhak D., McCarthy F., Wichmann C., Steger M., Ohmayer U., Distler U., Kaspar-Schoenefeld S., et al. MaxDIA enables library-based and library-free data-independent acquisition proteomics. Nat. Biotechnol. 2021;39:1563&#x2013;1573. doi: 10.1038/s41587-021-00968-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00968-7</ArticleId><ArticleId IdType="pmc">PMC8668435</ArticleId><ArticleId IdType="pubmed">34239088</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntel J., Gandhi T., Verbeke L., Bernhardt O.M., Treiber T., Bruderer R., Reiter L. Surpassing 10000 identified and quantified proteins in a single run by optimizing current LC-MS instrumentation and data analysis strategy. Mol. Omics. 2019;15:348&#x2013;360. doi: 10.1039/c9mo00082h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c9mo00082h</ArticleId><ArticleId IdType="pubmed">31465043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Tan Z., Xue P., Wang Y., Li X., Guan F. High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition/mass spectrometry (&#x201c;HIAP-DIA&#x201d;) Proteomics. 2021;21:e2000264. doi: 10.1002/pmic.202000264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.202000264</ArticleId><ArticleId IdType="pubmed">33460299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta D., Scandola S., Uhrig R.G. BoxCar and Library-Free Data-Independent Acquisition Substantially Improve the Depth, Range, and Completeness of Label-Free Quantitative Proteomics. Anal. Chem. 2022;94:793&#x2013;802. doi: 10.1021/acs.analchem.1c03338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c03338</ArticleId><ArticleId IdType="pubmed">34978796</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier F., Geyer P.E., Virreira Winter S., Cox J., Mann M. BoxCar acquisition method enables single-shot proteomics at a depth of 10,000 proteins in 100 minutes. Nat. Methods. 2018;15:440&#x2013;448. doi: 10.1038/s41592-018-0003-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-018-0003-5</ArticleId><ArticleId IdType="pubmed">29735998</ArticleId></ArticleIdList></Reference><Reference><Citation>Salovska B., Li W., Di Y., Liu Y. BoxCarmax: A High-Selectivity Data-Independent Acquisition Mass Spectrometry Method for the Analysis of Protein Turnover and Complex Samples. Anal. Chem. 2021;93:3103&#x2013;3111. doi: 10.1021/acs.analchem.0c04293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c04293</ArticleId><ArticleId IdType="pmc">PMC8959401</ArticleId><ArticleId IdType="pubmed">33533601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaun A., Lewis Hardell K.N., Olsson N., O&#x2019;Brien J.J., Gollapudi S., Smith M., McAlister G., Huguet R., Keyser R., Buffenstein R., et al. Automated 16-Plex Plasma Proteomics with Real-Time Search and Ion Mobility Mass Spectrometry Enables Large-Scale Profiling in Naked Mole-Rats and Mice. J. Proteome Res. 2021;20:1280&#x2013;1295. doi: 10.1021/acs.jproteome.0c00681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00681</ArticleId><ArticleId IdType="pubmed">33499602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert A.S., Prasad S., Belford M.W., Bailey D.J., McAlister G.C., Abbatiello S.E., Huguet R., Wouters E.R., Dunyach J.J., Brademan D.R., et al. Comprehensive Single-Shot Proteomics with FAIMS on a Hybrid Orbitrap Mass Spectrometer. Anal. Chem. 2018;90:9529&#x2013;9537. doi: 10.1021/acs.analchem.8b02233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.8b02233</ArticleId><ArticleId IdType="pmc">PMC6145172</ArticleId><ArticleId IdType="pubmed">29969236</ArticleId></ArticleIdList></Reference><Reference><Citation>He B., Huang Z., Huang C., Nice E.C. Clinical applications of plasma proteomics and peptidomics: Towards precision medicine. Proteom. Clin. Appl. 2022:e2100097. doi: 10.1002/prca.202100097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.202100097</ArticleId><ArticleId IdType="pubmed">35490333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bache N., Geyer P.E., Bekker-Jensen D.B., Hoerning O., Falkenby L., Treit P.V., Doll S., Paron I., Muller J.B., Meier F., et al. A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics. Mol. Cell Proteom. 2018;17:2284&#x2013;2296. doi: 10.1074/mcp.TIR118.000853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.TIR118.000853</ArticleId><ArticleId IdType="pmc">PMC6210218</ArticleId><ArticleId IdType="pubmed">30104208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D., Hassan M.I. Ultra-sensitive techniques for detecting neurological biomarkers: Prospects for early diagnosis. Biochem Biophys. Res. Commun. 2021;584:15&#x2013;18. doi: 10.1016/j.bbrc.2021.10.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.10.073</ArticleId><ArticleId IdType="pubmed">34753063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole K.H., Luptak A. High-throughput methods in aptamer discovery and analysis. Methods Enzymol. 2019;621:329&#x2013;346. doi: 10.1016/bs.mie.2019.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mie.2019.02.009</ArticleId><ArticleId IdType="pubmed">31128787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.C., Tzeng S.C., Peck K. Aptamer microarray as a novel bioassay for protein-protein interaction discovery and analysis. Biosens. Bioelectron. 2013;42:248&#x2013;255. doi: 10.1016/j.bios.2012.10.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2012.10.082</ArticleId><ArticleId IdType="pubmed">23208094</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Chen X., Fu X., Li Z., Huang Y., Liang C. Advances in Aptamer-Based Biomarker Discovery. Front. Cell Dev. Biol. 2021;9:659760. doi: 10.3389/fcell.2021.659760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.659760</ArticleId><ArticleId IdType="pmc">PMC8007916</ArticleId><ArticleId IdType="pubmed">33796540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sielaff M., Kuharev J., Bohn T., Hahlbrock J., Bopp T., Tenzer S., Distler U. Evaluation of FASP, SP3, and iST Protocols for Proteomic Sample Preparation in the Low Microgram Range. J. Proteome Res. 2017;16:4060&#x2013;4072. doi: 10.1021/acs.jproteome.7b00433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.7b00433</ArticleId><ArticleId IdType="pubmed">28948796</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan R., Sethi M.K., Zaia J. On-slide tissue digestion for mass spectrometry based glycomic and proteomic profiling. MethodsX. 2019;6:2329&#x2013;2347. doi: 10.1016/j.mex.2019.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mex.2019.09.029</ArticleId><ArticleId IdType="pmc">PMC6807300</ArticleId><ArticleId IdType="pubmed">31660297</ArticleId></ArticleIdList></Reference><Reference><Citation>Scicchitano M.S., Dalmas D.A., Boyce R.W., Thomas H.C., Frazier K.S. Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry. J. Histochem. Cytochem. 2009;57:849&#x2013;860. doi: 10.1369/jhc.2009.953497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/jhc.2009.953497</ArticleId><ArticleId IdType="pmc">PMC2728129</ArticleId><ArticleId IdType="pubmed">19471015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsa G., Guo Q., Goncalves C., Preston S.E.J., Lacasse V., Aguilar-Mahecha A., Benlimame N., Basik M., Spatz A., Batist G., et al. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. Int. J. Mol. Sci. 2022;23:4443. doi: 10.3390/ijms23084443.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23084443</ArticleId><ArticleId IdType="pmc">PMC9031572</ArticleId><ArticleId IdType="pubmed">35457260</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimel B.A., Pan S., May D.H., Shaffer S.A., Goodlett D.R., McIntosh M.W., Yerian L.M., Bronner M.P., Chen R., Brentnall T.A. Proteomics on Fixed Tissue Specimens-A Review. Curr. Proteom. 2009;6:63&#x2013;69. doi: 10.2174/157016409787847420.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157016409787847420</ArticleId><ArticleId IdType="pmc">PMC2760948</ArticleId><ArticleId IdType="pubmed">19829741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg E., Borner G.H.H. Spatial proteomics: A powerful discovery tool for cell biology. Nat. Rev. Mol. Cell Biol. 2019;20:285&#x2013;302. doi: 10.1038/s41580-018-0094-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0094-y</ArticleId><ArticleId IdType="pubmed">30659282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y., Wang X., Huang P., Tian R. Spatial proteomics for understanding the tissue microenvironment. Analyst. 2021;146:3777&#x2013;3798. doi: 10.1039/d1an00472g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d1an00472g</ArticleId><ArticleId IdType="pubmed">34042124</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J.J.H., Crook O.M., Borgeaud A.C., Cattin-Ortola J., Peak-Chew S.Y., Breckels L.M., Gillingham A.K., Chadwick J., Lilley K.S., Munro S. Spatial proteomics defines the content of trafficking vesicles captured by golgin tethers. Nat. Commun. 2020;11:5987. doi: 10.1038/s41467-020-19840-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19840-4</ArticleId><ArticleId IdType="pmc">PMC7689464</ArticleId><ArticleId IdType="pubmed">33239640</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro-Romero A., Montpeyo M., Martinez-Vicente M. The Emerging Role of the Lysosome in Parkinson&#x2019;s Disease. Cells. 2020;9:2399. doi: 10.3390/cells9112399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112399</ArticleId><ArticleId IdType="pmc">PMC7692401</ArticleId><ArticleId IdType="pubmed">33147750</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelen-Lee J., Blokhuis A.M., Spliet W.G.M., Pasterkamp R.J., Aronica E., Demmers J.A.A., Broekhuizen R., Nardo G., Bovenschen N., Van Den Berg L.H. Proteomic profiling of the spinal cord in ALS: Decreased ATP5D levels suggest synaptic dysfunction in ALS pathogenesis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:210&#x2013;220. doi: 10.1080/21678421.2016.1245757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1245757</ArticleId><ArticleId IdType="pubmed">27899032</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P., Weydt P., Thal D.R., Weishaupt J.H., Ludolph A.C., Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139:119&#x2013;134. doi: 10.1007/s00401-019-02093-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02093-x</ArticleId><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Morderer D., Wren M.C., Vettleson-Trutza S.A., Wang Y., Rabichow B.E., Salemi M.R., Phinney B.S., Oskarsson B., Dickson D.W., et al. Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation. Acta Neuropathol. Commun. 2022;10:22. doi: 10.1186/s40478-022-01322-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-022-01322-x</ArticleId><ArticleId IdType="pmc">PMC8842533</ArticleId><ArticleId IdType="pubmed">35164882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H., Hornburg D., Czuppa M., Bader J., Michaelsen M., Farny D., Arzberger T., Mann M., Meissner F., Edbauer D. Proteomics and C9orf72 neuropathology identify ribosomes as poly-GR/PR interactors driving toxicity. Life Sci. Alliance. 2018;1:e201800070. doi: 10.26508/lsa.201800070.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201800070</ArticleId><ArticleId IdType="pmc">PMC6238541</ArticleId><ArticleId IdType="pubmed">30456350</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E., Charles P.D., Finelli M.J., Scott C., Kessler B.M., Fischer R., Ansorge O., Gray E., Talbot K., Turner M.R. Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP. Brain Pathol. 2021;31:e12923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412074</ArticleId><ArticleId IdType="pubmed">33300249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman M.S., Beri J., Enders J.R., Nash T. Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS. Sci. Rep. 2018;8:16334. doi: 10.1038/s41598-018-34642-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34642-x</ArticleId><ArticleId IdType="pmc">PMC6218542</ArticleId><ArticleId IdType="pubmed">30397248</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Lee A., Nouwens A., Henderson R.D., McCombe P.A. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph. Lateral Scler. Front. Degener. 2018;19:362&#x2013;376. doi: 10.1080/21678421.2018.1433689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1433689</ArticleId><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty L., Henderson R.D., McCombe P.A., Lee A. Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2020;21:631&#x2013;634. doi: 10.1080/21678421.2020.1779303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779303</ArticleId><ArticleId IdType="pubmed">32558599</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Thezenas M.L., Charles P.D., Evetts S., Hu M.T., Talbot K., Fischer R., Kessler B.M., Turner M.R. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann. Neurol. 2018;83:258&#x2013;268. doi: 10.1002/ana.25143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P., Oeckl P., Steinacker P., Al Shweiki M.R., Weishaupt J.H., Landwehrmeyer G.B., Anderl-Straub S., Weydt P., Diehl-Schmid J., Danek A., et al. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J. Neurol. Neurosurg. Psychiatry. 2020;91:503&#x2013;511. doi: 10.1136/jnnp-2019-322476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322476</ArticleId><ArticleId IdType="pubmed">32132225</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Mager I., Thezenas M.L., Charles P.D., Talbot K., Fischer R., Kessler B.M., Wood M., Turner M.R. CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. Clin. Proteom. 2020;17:31. doi: 10.1186/s12014-020-09294-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-020-09294-7</ArticleId><ArticleId IdType="pmc">PMC7433176</ArticleId><ArticleId IdType="pubmed">32821252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi N., Doi H., Kurata Y., Kagawa H., Atobe Y., Funakoshi K., Tada M., Katsumoto A., Tanaka K., Kunii M., et al. Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurosci. Res. 2020;160:43&#x2013;49. doi: 10.1016/j.neures.2019.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2019.10.010</ArticleId><ArticleId IdType="pubmed">31669371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P.C., Wu D., Hu C.J., Chen H.Y., Hsieh Y.C., Huang C.C. Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: A longitudinal follow-up study. J. Neurol. Sci. 2020;418:117070. doi: 10.1016/j.jns.2020.117070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117070</ArticleId><ArticleId IdType="pubmed">32836016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramazi S., Zahiri J. Posttranslational modifications in proteins: Resources, tools and prediction methods. Database. 2021;2021:baab012. doi: 10.1093/database/baab012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baab012</ArticleId><ArticleId IdType="pmc">PMC8040245</ArticleId><ArticleId IdType="pubmed">33826699</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebersold R., Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537:347&#x2013;355. doi: 10.1038/nature19949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19949</ArticleId><ArticleId IdType="pubmed">27629641</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonara K., Andonovski M., Coorssen J.R. Proteomes Are of Proteoforms: Embracing the Complexity. Proteomes. 2021;9:38. doi: 10.3390/proteomes9030038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/proteomes9030038</ArticleId><ArticleId IdType="pmc">PMC8482110</ArticleId><ArticleId IdType="pubmed">34564541</ArticleId></ArticleIdList></Reference><Reference><Citation>Didonna A., Benetti F. Post-translational modifications in neurodegeneration. AIMS Biophys. 2016;3:27&#x2013;49.</Citation></Reference><Reference><Citation>Suk T.R., Rousseaux M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F., Obi T., Shishido T., Akatsu H., Murayama S., Saito Y., Yoshida M., Hasegawa M. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 2016;6:23281. doi: 10.1038/srep23281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23281</ArticleId><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F., Maniecka Z., P&#xe9;rez-Berlanga M., Hruska-Plochan M., Gilhespy L., Hock E.M., Wagner U., Afroz T., Boersema P.J., Barmettler G., et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci. 2019;22:65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Sandberg A., Araujo J.E., Cvetkovski F., Berglund E., Eriksson L.E., Pernemalm M. Evaluation of Spin Columns for Human Plasma Depletion to Facilitate MS-Based Proteomics Analysis of Plasma. J. Proteome Res. 2021;20:4610&#x2013;4620. doi: 10.1021/acs.jproteome.1c00378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00378</ArticleId><ArticleId IdType="pmc">PMC8419864</ArticleId><ArticleId IdType="pubmed">34320313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P.Y., Osman J., Low T.Y., Jamal R. Plasma/serum proteomics: Depletion strategies for reducing high-abundance proteins for biomarker discovery. Bioanalysis. 2019;11:1799&#x2013;1812. doi: 10.4155/bio-2019-0145.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2019-0145</ArticleId><ArticleId IdType="pubmed">31617391</ArticleId></ArticleIdList></Reference><Reference><Citation>El Rassi Z., Puangpila C. Liquid-phase based separation systems for depletion, prefractionation, and enrichment of proteins in biological fluids and matrices for in-depth proteomics analysis-An update covering the period 2014&#x2013;2016. Electrophoresis. 2017;38:150&#x2013;161. doi: 10.1002/elps.201600413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/elps.201600413</ArticleId><ArticleId IdType="pubmed">27730653</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshishian H., Burgess M.W., Specht H., Wallace L., Clauser K.R., Gillette M.A., Carr S.A. Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry. Nat. Protoc. 2017;12:1683&#x2013;1701. doi: 10.1038/nprot.2017.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2017.054</ArticleId><ArticleId IdType="pmc">PMC6057147</ArticleId><ArticleId IdType="pubmed">28749931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I., Lombardi V., Bremang M., Mitra V., Nardo G., Adiutori R., Lu C.H., Leoni E., Yip P., Yildiz O., et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol. Neurodegener. 2018;13:60. doi: 10.1186/s13024-018-0292-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0292-2</ArticleId><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E., Bremang M., Mitra V., Zubiri I., Jung S., Lu C.H., Adiutori R., Lombardi V., Russell C., Koncarevic S., et al. Author Correction: Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis. Sci. Rep. 2020;10:18603. doi: 10.1038/s41598-020-74974-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-74974-1</ArticleId><ArticleId IdType="pmc">PMC7584588</ArticleId><ArticleId IdType="pubmed">33097756</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Khademi M., Lindhe O., Jonsson G., Piehl F., Olsson T., Kockum I. Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers. Mol. Cell Proteom. 2021;20:100157. doi: 10.1016/j.mcpro.2021.100157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcpro.2021.100157</ArticleId><ArticleId IdType="pmc">PMC8554621</ArticleId><ArticleId IdType="pubmed">34597789</ArticleId></ArticleIdList></Reference><Reference><Citation>Macron C., Nunez Galindo A., Cominetti O., Dayon L. A Versatile Workflow for Cerebrospinal Fluid Proteomic Analysis with Mass Spectrometry: A Matter of Choice between Deep Coverage and Sample Throughput. Methods Mol. Biol. 2019;2044:129&#x2013;154. doi: 10.1007/978-1-4939-9706-0_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9706-0_9</ArticleId><ArticleId IdType="pubmed">31432411</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese A.M., Sharma A., Mishra P., Vijayalakshmi K., Harsha H.C., Sathyaprabha T.N., Bharath S.M., Nalini A., Alladi P.A., Raju T.R. Chitotriosidase-a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin. Proteom. 2013;10:19. doi: 10.1186/1559-0275-10-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinnell J.R., Cui M., Tieu K. Exosomes in Parkinson disease. J. Neurochem. 2021;157:413&#x2013;428. doi: 10.1111/jnc.15288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15288</ArticleId><ArticleId IdType="pmc">PMC8863192</ArticleId><ArticleId IdType="pubmed">33372290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N., Gu D., Meng M., Gordon M.L. TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer&#x2019;s Disease. Front. Aging Neurosci. 2020;12:166. doi: 10.3389/fnagi.2020.00166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00166</ArticleId><ArticleId IdType="pmc">PMC7287025</ArticleId><ArticleId IdType="pubmed">32581773</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetzl E.J., Abner E.L., Jicha G.A., Kapogiannis D., Schwartz J.B. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer&#x2019;s disease. FASEB J. 2018;32:888&#x2013;893. doi: 10.1096/fj.201700731R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700731R</ArticleId><ArticleId IdType="pmc">PMC5888398</ArticleId><ArticleId IdType="pubmed">29025866</ArticleId></ArticleIdList></Reference><Reference><Citation>Licker V., Turck N., K&#xf6;vari E., Burkhardt K., C&#xf4;te M., Surini-Demiri M., Lobrinus J.A., Sanchez J.C., Burkhard P.R. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson&#x2019;s disease pathogenesis. Proteomics. 2014;14:784&#x2013;794. doi: 10.1002/pmic.201300342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201300342</ArticleId><ArticleId IdType="pubmed">24449343</ArticleId></ArticleIdList></Reference><Reference><Citation>Petyuk V.A., Yu L., Olson H.M., Yu F., Clair G., Qian W.J., Shulman J.M., Bennett D.A. Proteomic Profiling of the Substantia Nigra to Identify Determinants of Lewy Body Pathology and Dopaminergic Neuronal Loss. J. Proteome Res. 2021;20:2266&#x2013;2282. doi: 10.1021/acs.jproteome.0c00747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00747</ArticleId><ArticleId IdType="pmc">PMC9190253</ArticleId><ArticleId IdType="pubmed">33900085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelliah S.S., Bhuvanendran S., Magalingam K.B., Kamarudin M.N.A., Radhakrishnan A.K. Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson&#x2019;s disease: A systematic review of proteomics studies. Ageing Res. Rev. 2022;73:101514. doi: 10.1016/j.arr.2021.101514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101514</ArticleId><ArticleId IdType="pubmed">34798300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Yin X., Yu H., Liu X., Yang F., Yao J., Jin H., Yang P. Quantitative proteomic analysis of serum proteins in patients with Parkinson&#x2019;s disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Analyst. 2012;137:490&#x2013;495. doi: 10.1039/c1an15551b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c1an15551b</ArticleId><ArticleId IdType="pubmed">22108571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu L., Dong M.X., Huang Y.L., Lu C.Q., Qian Q., Zhang C.C., Xu X.M., Liu Y., Chen G.H., Wei Y.D. Integrated Metabolomics and Proteomics Analysis Reveals Plasma Lipid Metabolic Disturbance in Patients With Parkinson&#x2019;s Disease. Front. Mol. Neurosci. 2020;13:80. doi: 10.3389/fnmol.2020.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00080</ArticleId><ArticleId IdType="pmc">PMC7344253</ArticleId><ArticleId IdType="pubmed">32714143</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Stewart T., Shi M., Pottiez G., Dator R., Wu R., Aro P., Schuster R.J., Ginghina C., Pan C., et al. An alpha-synuclein MRM assay with diagnostic potential for Parkinson&#x2019;s disease and monitoring disease progression. Proteom. Clin. Appl. 2017;11:1700045. doi: 10.1002/prca.201700045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201700045</ArticleId><ArticleId IdType="pmc">PMC5540649</ArticleId><ArticleId IdType="pubmed">28319654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., Srulijes K., Trojanowski J.Q., Lee V.M., Siderowf A.D., et al. Phosphorylated alpha-synuclein in Parkinson&#x2019;s disease. Sci. Transl. Med. 2012;4:121ra120. doi: 10.1126/scitranslmed.3002566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002566</ArticleId><ArticleId IdType="pmc">PMC3302662</ArticleId><ArticleId IdType="pubmed">22344688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno M.S., Lane M., Zhang W., Wolf P., Oliva P., Viel C., Wills A.M., Alcalay R.N., Scherzer C.R., Shihabuddin L.S., et al. Cerebrospinal fluid proteomics implicates the granin family in Parkinson&#x2019;s disease. Sci. Rep. 2020;10:2479. doi: 10.1038/s41598-020-59414-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-59414-4</ArticleId><ArticleId IdType="pmc">PMC7015906</ArticleId><ArticleId IdType="pubmed">32051502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C., Hopfner F., Katsikoudi A., Hein R., Catli C., Evetts S., Huang Y., Wang H., Ryder J.W., Kuhlenbaeumer G., et al. Serum neuronal exosomes predict and differentiate Parkinson&#x2019;s disease from atypical parkinsonism. J. Neurol. Neurosurg. Psychiatry. 2020;91:720&#x2013;729. doi: 10.1136/jnnp-2019-322588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322588</ArticleId><ArticleId IdType="pmc">PMC7361010</ArticleId><ArticleId IdType="pubmed">32273329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y., Kojima M., Kurosawa T., Sasaki R., Ichihara S., Hiraku Y., Tomimoto H., Murata M., Oikawa S. Proteomic Profiling of Exosomal Proteins for Blood-based Biomarkers in Parkinson&#x2019;s Disease. Neuroscience. 2018;392:121&#x2013;128. doi: 10.1016/j.neuroscience.2018.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.09.017</ArticleId><ArticleId IdType="pubmed">30266682</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M., Liu C., Cook T.J., Bullock K.M., Zhao Y., Ginghina C., Li Y., Aro P., Dator R., He C., et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson&#x2019;s disease. Acta Neuropathol. 2014;128:639&#x2013;650. doi: 10.1007/s00401-014-1314-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1314-y</ArticleId><ArticleId IdType="pmc">PMC4201967</ArticleId><ArticleId IdType="pubmed">24997849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Guo Y., Wei L., Yu F., Yu B., Xu A. Long Noncoding RNA POU3F3 and alpha-Synuclein in Plasma L1CAM Exosomes Combined with beta-Glucocerebrosidase Activity: Potential Predictors of Parkinson&#x2019;s Disease. Neurotherapeutics. 2020;17:1104&#x2013;1119. doi: 10.1007/s13311-020-00842-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-020-00842-5</ArticleId><ArticleId IdType="pmc">PMC7609611</ArticleId><ArticleId IdType="pubmed">32236821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Li X., Li J.-D. The Roles of Post-translational Modifications on &#x3b1;-Synuclein in the Pathogenesis of Parkinson&#x2019;s Diseases. Front. Neurosci. 2019;13:381. doi: 10.3389/fnins.2019.00381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00381</ArticleId><ArticleId IdType="pmc">PMC6482271</ArticleId><ArticleId IdType="pubmed">31057362</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006;281:29739&#x2013;29752. doi: 10.1074/jbc.M600933200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600933200</ArticleId><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Burai R., Ait-Bouziad N., Chiki A., Lashuel H.A. Elucidating the Role of Site-Specific Nitration of alpha-Synuclein in the Pathogenesis of Parkinson&#x2019;s Disease via Protein Semisynthesis and Mutagenesis. J. Am. Chem. Soc. 2015;137:5041&#x2013;5052. doi: 10.1021/ja5131726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja5131726</ArticleId><ArticleId IdType="pubmed">25768729</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds P., Mann D.M., Allsop D. Phosphorylated alpha-synuclein as a potential biomarker for Parkinson&#x2019;s disease and related disorders. Expert Rev. Mol. Diagn. 2012;12:115&#x2013;117. doi: 10.1586/erm.12.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erm.12.5</ArticleId><ArticleId IdType="pubmed">22369370</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002;4:160&#x2013;164. doi: 10.1038/ncb748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb748</ArticleId><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., Mandel R.J., Muzyczka N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA. 2008;105:763&#x2013;768. doi: 10.1073/pnas.0711053105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711053105</ArticleId><ArticleId IdType="pmc">PMC2206610</ArticleId><ArticleId IdType="pubmed">18178617</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., Trojanowski J.Q., Mann D., Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated i.in alpha-synucleinopathy lesions. J. Biol. Chem. 2002;277:49071&#x2013;49076. doi: 10.1074/jbc.M208046200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M208046200</ArticleId><ArticleId IdType="pubmed">12377775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellie J.F., Higgs R.E., Ryder J.W., Major A., Beach T.G., Adler C.H., Merchant K., Knierman M.D. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson&#x2019;s disease brain tissue by intact protein mass spectrometry. Sci. Rep. 2014;4:5797. doi: 10.1038/srep05797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep05797</ArticleId><ArticleId IdType="pmc">PMC4107347</ArticleId><ArticleId IdType="pubmed">25052239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 2009;284:10211&#x2013;10222. doi: 10.1074/jbc.M809671200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809671200</ArticleId><ArticleId IdType="pmc">PMC2665075</ArticleId><ArticleId IdType="pubmed">19203998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara T., Tonegawa R., Ito G., Mitani S., Iwatsubo T. Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 2012;287:7098&#x2013;7109. doi: 10.1074/jbc.M111.237131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.237131</ArticleId><ArticleId IdType="pmc">PMC3293593</ArticleId><ArticleId IdType="pubmed">22232559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Prudent M., Fauvet B., Lashuel H.A., Girault H.H. Phosphorylation of alpha-Synuclein at Y125 and S129 alters its metal binding properties: Implications for understanding the role of alpha-Synuclein in the pathogenesis of Parkinson&#x2019;s Disease and related disorders. ACS Chem. Neurosci. 2011;2:667&#x2013;675. doi: 10.1021/cn200074d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn200074d</ArticleId><ArticleId IdType="pmc">PMC3369716</ArticleId><ArticleId IdType="pubmed">22860160</ArticleId></ArticleIdList></Reference><Reference><Citation>Na C.H., Sathe G., Rosenthal L.S., Moghekar A.R., Dawson V.L., Dawson T.M., Pandey A. Development of a novel method for the quantification of tyrosine 39 phosphorylated alpha- and beta-synuclein in human cerebrospinal fluid. Clin. Proteom. 2020;17:13. doi: 10.1186/s12014-020-09277-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-020-09277-8</ArticleId><ArticleId IdType="pmc">PMC7197159</ArticleId><ArticleId IdType="pubmed">32390785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohrfelt A., Zetterberg H., Andersson K., Persson R., Secic D., Brinkmalm G., Wallin A., Mulugeta E., Francis P.T., Vanmechelen E., et al. Identification of novel alpha-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem. Res. 2011;36:2029&#x2013;2042. doi: 10.1007/s11064-011-0527-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-011-0527-x</ArticleId><ArticleId IdType="pmc">PMC3183298</ArticleId><ArticleId IdType="pubmed">21674238</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker D.G., Lue L.F., Adler C.H., Shill H.A., Caviness J.N., Sabbagh M.N., Akiyama H., Serrano G.E., Sue L.I., Beach T.G., et al. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 2013;240:190&#x2013;204. doi: 10.1016/j.expneurol.2012.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.11.020</ArticleId><ArticleId IdType="pmc">PMC3720241</ArticleId><ArticleId IdType="pubmed">23201181</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan R., Sethi M.K., Klein J.A., Zaia J. Proteomics, Glycomics, and Glycoproteomics of Matrisome Molecules. Mol. Cell Proteom. 2019;18:2138&#x2013;2148. doi: 10.1074/mcp.R119.001543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.R119.001543</ArticleId><ArticleId IdType="pmc">PMC6823855</ArticleId><ArticleId IdType="pubmed">31471497</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan R., Hogan J.D., Labadorf A., Myers R.H., Zaia J. A glycomics and proteomics study of aging and Parkinson&#x2019;s disease in human brain. Sci. Rep. 2020;10:12804. doi: 10.1038/s41598-020-69480-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69480-3</ArticleId><ArticleId IdType="pmc">PMC7393382</ArticleId><ArticleId IdType="pubmed">32733076</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs M., Sethi M.K., Raghunathan R., Layne M.D., Zaia J. Matrisome changes in Parkinson&#x2019;s disease. Anal. Bioanal. Chem. 2022;414:3005&#x2013;3015. doi: 10.1007/s00216-022-03929-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-022-03929-4</ArticleId><ArticleId IdType="pmc">PMC8944212</ArticleId><ArticleId IdType="pubmed">35112150</ArticleId></ArticleIdList></Reference><Reference><Citation>Posavi M., Diaz-Ortiz M., Liu B., Swanson C.R., Skrinak R.T., Hernandez-Con P., Amado D.A., Fullard M., Rick J., Siderowf A., et al. Characterization of Parkinson&#x2019;s disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Med. 2019;16:e1002931. doi: 10.1371/journal.pmed.1002931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002931</ArticleId><ArticleId IdType="pmc">PMC6788685</ArticleId><ArticleId IdType="pubmed">31603904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerri S., Ghezzi C., Sampieri M., Siani F., Avenali M., Dornini G., Zangaglia R., Minafra B., Blandini F. The Exosomal/Total alpha-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients. Front. Cell Neurosci. 2018;12:125. doi: 10.3389/fncel.2018.00125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00125</ArticleId><ArticleId IdType="pmc">PMC5968118</ArticleId><ArticleId IdType="pubmed">29867358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Xie Z., Zhang X., Mao J., Wang M., Wei S., Fu Y., Zheng H., He Y., Chen H., et al. Investigation of alpha-Synuclein Species in Plasma Exosomes and the Oligomeric and Phosphorylated alpha-Synuclein as Potential Peripheral Biomarker of Parkinson&#x2019;s Disease. Neuroscience. 2021;469:79&#x2013;90. doi: 10.1016/j.neuroscience.2021.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2021.06.033</ArticleId><ArticleId IdType="pubmed">34186110</ArticleId></ArticleIdList></Reference><Reference><Citation>He T. Implementation of Proteomics in Clinical Trials. Proteom. Clin. Appl. 2019;13:e1800198. doi: 10.1002/prca.201800198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201800198</ArticleId><ArticleId IdType="pubmed">30702805</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Ravetti M., Moscato P. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer&#x2019;s disease. PLoS ONE. 2008;3:e3111. doi: 10.1371/journal.pone.0003111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003111</ArticleId><ArticleId IdType="pmc">PMC2518833</ArticleId><ArticleId IdType="pubmed">18769539</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr S.A., Abbatiello S.E., Ackermann B.L., Borchers C., Domon B., Deutsch E.W., Grant R.P., Hoofnagle A.N., Huttenhain R., Koomen J.M., et al. Targeted peptide measurements in biology and medicine: Best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell Proteom. 2014;13:907&#x2013;917. doi: 10.1074/mcp.M113.036095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M113.036095</ArticleId><ArticleId IdType="pmc">PMC3945918</ArticleId><ArticleId IdType="pubmed">24443746</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger J.R., Wybenga-Groot L.E., Tong J., Bache N., Tsao M.S., Moran M.F. Evosep One Enables Robust Deep Proteome Coverage Using Tandem Mass Tags while Significantly Reducing Instrument Time. J. Proteome Res. 2019;18:2346&#x2013;2353. doi: 10.1021/acs.jproteome.9b00082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.9b00082</ArticleId><ArticleId IdType="pubmed">30938160</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q., Liu Z., Bhawal R., Anderson E.T., Sherwood R.W., Yang Y., Thannhauser T., Schroyen M., Tang X., Zhang H., et al. Comparison of MS(2), synchronous precursor selection MS(3), and real-time search MS(3) methodologies for lung proteomes of hydrogen sulfide treated swine. Anal. Bioanal. Chem. 2021;413:419&#x2013;429. doi: 10.1007/s00216-020-03009-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-020-03009-5</ArticleId><ArticleId IdType="pubmed">33099676</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>